1 Min Read
March 29 (Reuters) - Cytokinetics Inc
* Cytokinetics announces start of second cohort in phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.